Janssen/Shire Reminyl
Executive Summary
Alzheimer's treatment slated for early 2001 launch after receipt of "approvable" letter July 31 from FDA, Shire said. While the agency has requested additional data, Janssen said it expects to be able to use currently available data to satisfy the request. Janssen filed the NDA for galantamine on Sept. 29, 1999